Form 4: Cocrystal Pharma Director Buys 20,000 Shares

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., acquired 20,000 shares of common stock at a weighted average price of $0.9655.

Summary

• Phillip Frost, MD, a Director and 10% owner of Cocrystal Pharma, Inc. (COCP), acquired 20,000 shares of common stock.
• The shares were purchased on December 30, 2025, at a weighted average price of $0.9655 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan.
• Following this transaction, Frost Gamma Investments Trust, for which Dr. Frost is the trustee, beneficially owns 1,788,551 shares indirectly.
• Additionally, 27,100 shares are directly owned by the reporting person, which include shares issuable upon vesting of restricted stock units.
• The reported price range for the acquired shares was $0.9635 to $0.9700.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director and 10% owner, especially under a 10b5-1 plan, generally indicates a positive sentiment and confidence in the company's future prospects. It's a direct investment by someone with intimate knowledge of the company.

Positives

• A Director and 10% owner, Phillip Frost, acquired 20,000 shares of common stock, indicating potential confidence in the company's future.
• The transaction was made under a Rule 10b5-1 plan, suggesting a pre-planned investment strategy rather than a reaction to immediate news.

Negatives

• NA

Risks

• NA

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• NA

Industry Context

Insider buying by a director and significant shareholder like Dr. Frost can sometimes be interpreted by the market as a sign of confidence in the company's prospects, potentially signaling an undervaluation or positive future developments, especially in the biotechnology or pharmaceutical sector where Cocrystal Pharma operates.

Comparison to Industry Standards

• Insider purchases, particularly by a director and 10% owner, are generally viewed positively. While specific comparable transactions are not detailed in this filing, such actions often align with a belief in the company's long-term value, a common sentiment among insiders in growth-oriented sectors like pharmaceuticals. For example, similar insider buys have been observed in companies like BioNTech or Moderna during key development phases, where management's personal investment signals conviction.

Related Party Transactions

• Acquisition of 20,000 common shares by Frost Gamma Investments Trust, where Phillip Frost M.D. is the trustee. Dr. Frost is also a Director and 10% owner of Cocrystal Pharma, Inc. This transaction is considered a related party dealing due to Dr. Frost's multiple roles and interests.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal, potentially increasing confidence in the stock.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The filing itself does not mention any specific future actions or milestones for the company. It solely reports a past insider transaction.

Key Dates

Recommendation

The insider purchase by a director and 10% owner, Phillip Frost, signals confidence in Cocrystal Pharma's future. While this is a positive indicator, a single transaction, even by a significant insider, typically warrants a 'hold' recommendation for seasoned investors unless supported by broader positive financial performance, strategic developments, or a compelling valuation argument not present in this Form 4 filing alone. It suggests the insider believes the stock is at least fairly valued or undervalued, but doesn't provide enough information for a strong buy signal.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Buy, Form 4, Stock Acquisition, Director Purchase, 10b5-1 Plan